It is widely recognized that cellular and gene therapies (also referred to as advanced cellular therapies) hold the potential to revolutionize health care for a variety of diseases. However, the limitations of current technologies, the complexity of manufacturing, safety, efficacy and reimbursement models and understanding regulatory requirements for cell-based and cell-derived products as therapies have led to only a few players making it to the commercial stages. The cell and gene therapy industry is yet to address certain gaps relating to these limitations that will facilitate clinical and commercial success of these therapies.
Key players all over the globe are also looking to tackle some crucial needs such as scalable manufacturing (upstream and downstream), robustness and efficiencies to make these advanced cellular therapies cost effective and safe.
Taking into consideration the above issues, the Bioprocessing of Advanced Cellular Therapies Congress took place on 2-3 June 2016 at the London Heathrow Marriott Hotel - UK and presented some of the recent developments, approaches and novel technologies for bioprocessing cellular therapies. The focus was on the engineering challenges faced in this field with respect to bioprocessing from early process development to manufacturing scales.
It aimed to support the delegates in successful translation of unique bioprocesses to robust, scaled manufacturing production for successful clinical translation. The two-day congress concluded with a summary into key aspects around regulatory requirements, business development and reimbursement insights.
• Upstream process development for gene therapies
• Upstream process development for cell based therapies
• Downstream processing considerations
• Analytics - tackling measurement assurance for advanced cellular therapeutics
• Insights into Business Development and Reimbursement
• Regulatory perspectives
Key Speakers at the Conference:
• Chris Mason, Professor Of Regenerative Medicine, University College Of London, UK
• Otto-Wilhelm Merten, Head Of The Applied Vectorology And Innovation, Généthon, France
• Bo Kara, Head Process Development, Advanced Therapy Delivery, GSK, UK
• Anne Plant, Program Director For Biosciences, NIST, USA
• Paula Marques Alves, Chief Executive Officer, IBET, Portugal
• Steve Oh, Director Stem Cell Bioprocessing, Bioprocessing Technology Institute, Singapore
• John Gray, VP, R&D, Audentes, USA
Post Show Report 2016:
Click here to view post show report of Bioprocessing of Advanced Cellular Therapies Congress 2016